跳至主要内容
临床试验/ISRCTN79871784
ISRCTN79871784已完成3 期

Efficacy and safety of gabapentin versus placebo to prevent the incidence of PostHerpetic Neuralgia: a double-blinded clinical trial

Primary Care Management of Mallorca (Gerencia de Atención Primaria de Mallorca) (Spain)0 个研究点目标入组 98 人开始时间: 2013年5月2日最近更新:
适应症

试验速览

阶段
3 期
状态
已完成
发起方
入组人数
98

研究概览

简要总结

研究设计

研究类型
Interventional

入排标准

性别
All

入选标准

  • 1. Patient aged 50 or above, either sex
  • 2. Patient diagnosed or uncomplicated herpes zoster within 72 hours of onset of the rash in patients with acute herpes zoster and with moderate/severe pain (Analogic visual scale = 4)

排除标准

  • 1. Patients taking gabapentin
  • 2. Patients diagnosed of severe hepatic impairment, hypersensitivity to gabapentin or excipients, acute renal failure or renal impairment (Clcr <79ml/min)
  • 3. Patients with evidence of cutaneous or visceral dissemination of herpes zoster infection (cutaneous dissemination is defined as 20 discrete lesions outside adjacent dermatomes) or ocular dissemination
  • 4. Immunocompromised state and/or interferon treatment in the last 4 weeks
  • 5. Patient taking tricyclic antidepressants or corticoids in the inclusion or treatment period

研究者

发起方
Primary Care Management of Mallorca (Gerencia de Atención Primaria de Mallorca) (Spain)

相似试验